NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026)

NewAmsterdam Pharma has disclosed Common Equity across 6 years of filings, most recently posting $665.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $665.2 million, down 14.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $665.2 million (down 14.43% YoY), and the FY2025 annual result was $683.4 million, down 9.78% from the prior year.
• Common Equity came in at $665.2 million for Q1 2026 at NewAmsterdam Pharma, down from $683.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $778.5 million in Q2 2025 to a low of $288.4 million in Q4 2023.
• The 5-year median for Common Equity is $453.1 million (2022), against an average of $532.5 million.
• Across the five-year window, Common Equity soared 767.87% in 2022 and plunged 41.66% in 2023, its largest moves.
• NewAmsterdam Pharma's Common Equity stood at $494.3 million in 2022, then slumped by 41.66% to $288.4 million in 2023, then soared by 162.66% to $757.5 million in 2024, then retreated by 9.78% to $683.4 million in 2025, then dropped by 2.66% to $665.2 million in 2026.
• The last three Common Equity figures came in at $665.2 million (Q1 2026), $683.4 million (Q4 2025), and $728.1 million (Q3 2025), per Business Quant data.